Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Saved in:
Format: | article |
---|---|
Language: | EN |
Published: |
BMJ Publishing Group
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/839aaab9b4554eddb78c18a7f48b942e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
by: Leisha A Emens, et al.
Published: (2021) -
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
by: Julia Foldi, et al.
Published: (2021) -
Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases
by: Yizhao Xie, et al.
Published: (2021) -
Targeting nucleotide metabolism enhances the efficacy of anthracyclines and anti-metabolites in triple-negative breast cancer
by: Craig Davison, et al.
Published: (2021) -
A triple negative breast cancer: what it is not!
by: Katakkar SB
Published: (2012)